| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 20, 2024 |
| Accession Number: | 0001628280-24-048044 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 20, 2024 |
| Accession Number: | 0001628280-24-048044 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2024 | Outperform → Peer Perform | Wolfe Research | |
| 7/19/2023 | $69.00 | Outperform | Robert W. Baird |
| 7/13/2023 | $70.00 | Overweight | KeyBanc Capital Markets |
| 5/23/2023 | $75.00 | Buy | CL King |
| 4/14/2023 | $75.00 | Buy | Mizuho |
| 3/24/2023 | $71.00 | Hold → Buy | Needham |
| 10/21/2022 | $85.00 | Outperform | RBC Capital Mkts |
| 10/12/2022 | $75.00 | Hold | Jefferies |
4 - Axonics, Inc. (0001603756) (Issuer)
4 - Axonics, Inc. (0001603756) (Issuer)
4 - Axonics, Inc. (0001603756) (Issuer)
MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisiti
Axonics, Inc. (NASDAQ:AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. "Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year," said Raymond W. Cohen, chief executive officer. "Revenue growth for both sacral neuromodulation and Bulkamid® was driven by higher utilization at existing customers and the onboarding of new accounts." Mr. Cohen continued, "Our commitment to innovation, quality, direct-to-consumer advertising and providing str
Axonics, Inc. (NASDAQ:AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15®) and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20
EFFECT - Axonics, Inc. (0001603756) (Filer)
25-NSE - Axonics, Inc. (0001603756) (Subject)
POS AM - Axonics, Inc. (0001603756) (Filer)
SC 13G/A - Axonics, Inc. (0001603756) (Subject)
SC 13G/A - Axonics, Inc. (0001603756) (Subject)
SC 13G/A - Axonics, Inc. (0001603756) (Subject)
Needham analyst Mike Matson reiterates Axonics (NASDAQ:AXNX) with a Hold.
Axonics (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.08) by 375 percent. This is a 100 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $91.41 million which beat the analyst consensus estimate of $89.59 million by 2.03 percent. This is a 29.38 percent increase over sales of $70.65 million the same period last year.
Wolfe Research downgraded Axonics Modulation from Outperform to Peer Perform
Robert W. Baird initiated coverage of Axonics Modulation with a rating of Outperform and set a new price target of $69.00
KeyBanc Capital Markets initiated coverage of Axonics Modulation with a rating of Overweight and set a new price target of $70.00
MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for the period, compared to $0.45 a year ago.
Generated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2023. "Our commercial team continues to execute at a high level, generating over 30% revenue growth in the third quarter," said Raymond W. Cohen, chief executive officer. "Our growth was driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts. Based on the s
Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 3Q23 registration. For those not planning to ask a question, the company recommends accessing the conference call by webcast at the following link: Axonics 3Q23 webcast. A replay of the webcast will be archived in t
Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer
BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.
Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice president of finance and accounting, will succeed Mr. Dearen on Monday, October 2. "On behalf of the Axonics team and the board of directors, I want to thank Dan, my co-founder and longtime colleague, for his many contributions to the company over the last 10 years," said Raymond W. Cohen, chief executive officer. "Dan has played an instrumental role in Axonics' success and the significant value that